Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus

详细信息	查看全文 | 推荐本文 |

• 作者：Beatriz Tavira^a ; Eliecer Coto^a ; ^k ; ^{eliecer.coto@sespa.princast.es} ; Armando Torres^b ; ^j ; Carmen Dí ; az-Corte^c ; Beatriz Dí ; az-Molina^d ; Francisco Ortega^c ; ^j ; ^k ; Manuel Arias^e ; ^j ; Juan M. Dí ; az^f ; Rafael Selgas^g ; ^j ; Carlos Ló ; pez-Larrea^h ; ^j ; Marta Ruiz-Ortegaⁱ ; Alberto Ortizⁱ ; Elena Gonzá ; lez^g ; Josep M. Campistol^j ; Victoria Alvarez^a ; The Pharmacogenetics of tacrolimus REDINREN study group¹
• 关键词：Postransplant diabetes ; KCNJ11 ; Genetic association
• 刊名：Molecular Genetics and Metabolism
• 出版年：2012
• 期刊代码：175_10967192
• 类别：bio
• 出版时间：March, 2012
• 卷：105
• 期：3
• 页码：525-527
• 文件大小：147 K

摘要

KCNJ11 polymorphisms have been linked to the risk of developing type 2 diabetes. Our aim was to define the contribution of KCNJ11 to new-onset diabetes after transplantation (NODAT) among patients treated with Tacrolimus (Tac). A total of 115 NODAT and 205 non-NODAT were genotyped for rs5219 (p.E23K). AA + AG genotypes were significantly associated with NODAT-risk (p = 0.004; OR = 2.10). The reported effect of this KCNJ11 polymorphism on insulin release by beta cells could explain this association.